Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata
A Two Stage Phase II Randomized Bilateral Comparison of Topical Targretin® Gel 1% in Alopecia Areata
Sponsor: Ligand Pharmaceuticals
A PHASE2/PHASE3 clinical study on Alopecia Areata, this trial is completed. The trial is conducted by Ligand Pharmaceuticals and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2/PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2_PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE2_PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE2_PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2_PHASE3
First recorded
May 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Ligand Pharmaceuticals
- M.D. Anderson Cancer Center
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Houston, United States